The numbers back this up. In an analysis of nearly 16,000 sites across 151 global Phase II/III trials, 11% of sites ready to recruit enrolled zero patients, and only 47% of studies finished enrollment on schedule — one in six took more than twice as long as planned, according to Applied Clinical Trials' 2012 enrollment analysis. Poor country selection is frequently at the root of these failures.
This guide breaks down the factors that actually move the needle, and how to build a framework that reduces guesswork.
TL;DR
- Country selection shapes regulatory timelines, recruitment speed, cost, and data quality, not just logistics
- Prioritize regulatory environment, patient population, site capability, and operational feasibility
- A structured, evidence-based framework beats relying on investigator estimates alone
- Working with a global CRO that has local expertise makes cross-region decisions faster and safer
What Does Country Selection Mean in a Multinational Clinical Trial?
A multi-regional clinical trial (MRCT) enrolls patients across multiple countries under one protocol, usually to speed up recruitment, capture diverse patient populations, and support simultaneous global regulatory filings. Sponsors expand beyond a single country because no single market can deliver enough eligible patients fast enough, especially for rare diseases or competitive indications.
Country selection becomes most critical from Phase II through Phase IV, when protocols require larger, more diverse populations and sponsors start planning for regulatory submissions in multiple markets simultaneously.
Why Country Selection Is a Strategic, Not Administrative, Decision
Choosing countries is a portfolio decision, not a checkbox exercise handed off to whoever has spare site relationships. It balances speed, enrollment volume, data quality, cost, and regulatory relevance—often against each other.
There's no universal "best" country. A market that's ideal for an oncology trial may be entirely wrong for a rare pediatric indication. The right mix depends on:
- The protocol's inclusion/exclusion criteria
- Disease prevalence versus actual referral pathways
- Regulatory strategy (where you ultimately want to file)
- Competitive trial density in that indication
Key Factors to Consider When Selecting Countries for a Multinational Trial
These factors connect operational realities on the ground to enrollment success and regulatory approval. Skipping any one of them tends to surface as a delay later.
Regulatory and Ethical Approval Landscape
Regulatory timelines vary widely, and that variability directly affects time-to-first-patient-in. The FDA requires sponsors to wait 30 calendar days after IND submission before starting a trial, allowing time for a safety review, per the FDA's IND guidance.
Under the EU's Clinical Trials Regulation, the assessment phase caps at 45 days but authorization still sits with individual member states. CTR harmonizes the process, not the outcome. That distinction matters more than most sponsors expect.
Patient Population and Epidemiology
High disease prevalence doesn't guarantee an enrollable patient pool. The real funnel looks like this: diagnosed population → protocol-eligible → reachable → willing → screened → enrolled.
A 2024 breast cancer cohort study found 54% of screened patients were eligible, and 58% of those eligible actually enrolled, per NIH/PMC research. That gap between prevalence and usable capacity is exactly why local chart reviews and referral-pathway analysis matter more than national disease statistics.
KPI impact: screen failure rate, enrollment velocity.
Standard of Care and Patient Access
Local treatment pathways, diagnostic availability, and referral patterns determine whether patients who technically meet eligibility criteria are actually reachable. A country with high prevalence but limited diagnostic infrastructure may struggle to identify eligible patients quickly.
KPI impact: eligibility match rate.
Site Capability and Investigator Experience
Site infrastructure, staff qualifications, and historical trial performance predict how fast a site activates and how clean its data will be. Data quality is measurable: one analysis of 19 trials and over 108,000 case report form pages found query rates ranging from 0.035 to 1.149 per page depending on country, according to NIH/PMC research on data query rates.
KPI impact: site activation timelines, data query rates.
Cost and Budget Considerations
Site fees, regulatory costs, and patient compensation swing dramatically by region. Modeled estimates put regional site costs at roughly 49–59% of North American levels in Africa, Central Europe, the Middle East, and Latin America. Western Europe and Asia-Pacific land closer to 78%, per PubMed's 2019 globalization cost analysis. Treat these as directional, not quotable figures for any specific budget.
KPI impact: cost-per-patient-enrolled.
Competitive Trial Density and Operational Feasibility
Saturation from competing trials thins the available patient pool even in high-prevalence markets. IQVIA's 2024 report found the top 10 most-used countries account for 58% of average pipeline country use, so popular markets are often the most contested ones too.
Operational feasibility cuts the other way. Import/export requirements, customs delays, and cold-chain logistics can derail a country that looks perfect on paper.
KPI impact: recruitment competition index, IP shipment lead time.
Navigating Country-Specific Regulatory and Compliance Differences
Even harmonized regions still carry national-level quirks. The EU CTR is a good example: it coordinates a single assessment process, but member states retain authority over final approval, and requirements around language, fees, and legal representation still vary country by country.
Core compliance areas that differ by country include:
- Data protection standards (GDPR-equivalents and local variants)
- Import/export rules for clinical supplies
- Human subject protection standards
- GCP/GMP alignment and inspection expectations
- Language requirements for submissions and informed consent
Assuming one region-wide framework covers every country in it is a common and costly mistake. Local regulatory partners who understand these nuances help sponsors avoid inadvertent violations before they become submission delays.
Building a Country Feasibility Framework
Investigator estimates alone are a weak foundation for country decisions. Investigator estimates alone are a weak foundation for country decisions. They are often optimistic and rarely account for competing trials or referral bottlenecks. A structured, evidence-based feasibility template produces more reliable forecasts.
A solid feasibility assessment should cover:
- Patient availability: based on referral data and prescreen pilots, not prevalence alone
- Site network strength: historical activation speed and enrollment performance
- Start-up timeline: realistic regulatory and ethics review windows
- Cost profile: all-in costs, not just site fees
- Risk and mitigation plan: what happens if a country underperforms
Sequencing countries into waves protects your first-patient-in timeline and keeps enrollment capacity in reserve:
- Fast-start countries: proven regulatory speed and strong site history
- Second-wave countries: solid feasibility but slower start-up
- Contingency countries: held in reserve if fast-start markets underperform
This staged approach means a slow regulatory review in one country doesn't stall the entire trial.
How DRK Research Solutions Supports Global Country Selection
DRK Research Solutions helps sponsors evaluate and select countries by pairing site identification and feasibility assessments with on-the-ground operations across multiple continents. Local regulatory and operational expertise in both regulated and emerging markets informs which countries can realistically meet enrollment, timeline, and compliance goals.
DRK's country-selection support includes:
- A worldwide network with localized regulatory and operational expertise
- 100+ experienced professionals across Europe, the Middle East, Asia, Africa, and the Americas
- Strong reach in emerging markets to support diverse and underserved patient recruitment
- Patient-centric feasibility reviews that factor in local access, language, and referral pathways
- End-to-end CRO support spanning site identification, feasibility, monitoring, and study conduct
Conclusion
The right countries are the ones matched to your protocol's patient population, regulatory pathway, and timeline—not the ones that top popularity lists. A market that works well for one indication can be a poor fit for another. Country selection is not a one-and-done decision either. Standard of care shifts, competition intensifies, and regulations evolve, so feasibility should be revisited across the trial lifecycle, not only at start-up. Working with a CRO such as DRK Research Solutions, which combines global regulatory knowledge with local operational insight, helps you reassess country fit as conditions change and keep multinational timelines on track.
Frequently Asked Questions
Which country has the most clinical trials?
The United States leads global trial volume, with countries like Germany, France, and China also hosting large shares, according to WHO's clinical trial registry data. High volume reflects market activity, not guaranteed feasibility for your specific protocol.
What are the three types of clinical trials?
The main types are interventional (participants are assigned an intervention), observational (no assigned intervention), and expanded access for patients who do not qualify for standard trial enrollment.
How many countries are typically involved in a multinational clinical trial?
This varies by phase and indication. Pivotal Phase III trials average around 14 countries, though the right number depends on endpoint generalizability, disease distribution, and regulatory strategy.
What is the biggest challenge in selecting countries for a global trial?
Balancing patient access against regulatory complexity and start-up timelines is usually the toughest trade-off. A country with abundant eligible patients may carry a slower regulatory pathway that delays first-patient-in.
How does regulatory harmonization (like the EU CTR) affect country selection?
Harmonization simplifies the cross-border assessment process, but national differences in language, fees, and legal representation requirements still apply. Sponsors need country-by-country verification.
Why do sponsors include countries with slower start-up timelines?
Strategic value (patient access, investigator expertise, or future market relevance) can justify slower activation. A country critical for eventual market launch may be worth including despite a longer regulatory runway.
